Relative dose intensity in early stage breast cancer chemotherapy: A retrospective analysis of incidence, risk factors and outcomes at a south-west Sydney cancer clinic

Asia-Pacific Journal of Clinical Oncology

Volumn 9, Issue 4, 2013, Pages 365-372

  Sandy, Jessica ^a   Della Fiorentina, Stephen ^a  

^a Macarthur Cancer Therapy Centre   (Australia)

Author keywords

Adjuvant; Breast neoplasm; Chemotherapy; Physicians practice pattern; Risk assessment; Treatment outcome

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; PACLITAXEL;

ADULT; AGED; ALLERGIC REACTION; ARTICLE; BLOOD TOXICITY; BODY MASS; BONE PAIN; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CENTER; CANCER INCIDENCE; CANCER STAGING; CANCER SURVIVAL; CARDIOTOXICITY; CEREBROVASCULAR ACCIDENT; DIARRHEA; DISEASE FREE SURVIVAL; DRUG DOSE REDUCTION; HUMAN; INFECTION; LIVER TOXICITY; MAJOR CLINICAL STUDY; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; MYALGIA; NAUSEA; NEUROPATHY; OBESITY; OVERALL SURVIVAL; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK FACTOR; SKIN TOXICITY; TREATMENT OUTCOME; VOMITING; ADJUVANT CHEMOTHERAPY; AUSTRALIA; BREAST NEOPLASMS; DOSE RESPONSE; FEMALE; INCIDENCE; MIDDLE AGED; SURVIVAL;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AUSTRALIA; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; INCIDENCE; MIDDLE AGED; RETROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84888025920     PISSN: 17437555     EISSN: 17437563     Source Type: Journal    
DOI: 10.1111/ajco.12093     Document Type: Article

References (26)

1. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomized trials. Lancet 2005; 365: 1687-1717.
2. Budman DR, Berry DA, Cirrincione CT etal. Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer. J Natl Cancer Inst 1998; 90: 1205-1211.
3. Morrow T, Siegel M, Boone S, Lawless G, Carter W. Chemotherapy dose intensity determination as a quality of care measurement for managed care organisations in the treatment of early-stage breast cancer. Am J Med Qual 2002; 17: 218-224.
4. Wildiers H, Reiser M. Relative dose intensity of chemotherapy and its impact on outcomes in patients with early breast cancer or aggressive lymphoma. Crit Rev Oncol Hemtaol 2011; 77: 221-240.
5. Piccart MJ, Biganzoli L, Di Leo A. The impact of chemotherapy dose density and dose intensity on breast cancer outcome: what have we learned? Eur J Cancer 2000; 36 (Suppl. 1): S4-S10.
6. Bonadonna G, Valagussa P, Moliterni A etal. Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer; the results of 20 years follow-up. N Engl J Med 1995; 332: 901-906.
7. Lyman GH, Dale DC, Crawford J. Incidence and predictors of low dose-intensity in adjuvant breat cancer chemotherapy: a nationwide study of community practices. J Clin Oncol 2003; 21: 4524-4531.
8. Shayne M, Crawford J, Dale DC, Culakova E, Lyman GH. Predictors of reduced dose intensity in patients with early-stage breast cancer receiving adjuvant chemotherapy. Breast Cancer Res Treat 2006; 100: 255-262.
9. Raza S, Welch S, Younus J. Relative dose intensity delivered to patients with early breast cancer: Canadian experience. Curr Oncol 2009; 16: 8-12.
10. Wood WC, Budman DR, Korzun AH etal. Dose and dose intensity of adjuvant chemotherapy for stage II, node positive breast carcinoma. N Engl J Med 1994; 330: 1253-1259.
11. Leonard RC, Miles D, Thomas R, Nussey F, UK Breast Cancer Neutropenia Audit Group. Impact of neutropaenia on delivering planned adjuvant chemotherapy: UK audit of primary breast cancer patients. Br J Cancer 2003; 89: 2062-2068.
12. Shayne M, Culakova E, Peniewierski MS etal. Dose intensity and hematologic toxicity in older cancer patients receiving systemic chemotherapy. Cancer 2007; 110: 1611-1620.
13. Chang J. Chemotherapy dose reduction and delay in clinical practice: evaluating the risk to patient outcome in adjuvant chemotherapy for breast cancer. Eur J Cancer 2000; 36 (Suppl. 1): S11-14.
14. Lyman GH. Undertreatment of cancer patients with chemotherapy is a global concern. J Oncol Pract 2008; 4: 114-115.
15. Kuderer NM, Dale DC, Crawford J etal. Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropaenia and mortality in adult cancer patients receiving chemotherapy: a systemic review. J Clin Oncol 2007; 25: 3158-3167.
16. Muss HB, Berry DA, Cirrincione C etal. Toxicity of older and younger patients treated with adjuvant chemotherapy for node-positive breast cancer: the Cancer and Leukemia Group B Experience. J Clin Oncol 2007; 25: 3699-3704.
17. Field KM, Kosmider S, Jefford M etal. Chemotherapy dosing strategies in the obese, elderly, and thin patients: results of a nationwide survey. J Oncol Pract 2008; 4: 111-116.
18. Kummel S etal. Randomised trial: survival benefit and safety of adjuvant dose-dense chemotherapy for node-positive breast cancer. Br J Cancer 2006; 94: 1237-1244.
19. Griggs JJ, Sorbero ME, Lyman GH. Undertreatment of obese women receiving breast cancer chemotherapy. Arch Intern Med 2005; 165: 1267-1273.
20. Hunter RJ, Navo MA, Thaker PH, Bodurka DC, Wolf JK, Smith JA. Dosing chemotherapy in obese patients: actual versus assigned body surface area (BSA). Cancer Treat Rev 2009; 35: 69-78.
21. Calle EE, Rodriguez C, Walker-Thurmond D, Thun MJ. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of US adults. N Engl J Med 2003; 348: 1625-1638.
22. Petrelli JM, Calle EE, Rodriguez C etal. Body mass index, height, and postmenopausal breast cancer mortality in a prospective cohort of US women. Cancer Causes Control 2002; 13: 325-332.
23. Gianna AM, Piccart MJ. Optimising chemotherapy dose density and dose intensity: new strategies to improve outcomes in adjuvant therapy for breast cancer. Eur J Cancer 2000; 36: S1-3.
24. Lyman GH. Chemotherapy dose intensity and quality of cancer care. Oncology 2006; 20: 16-25.
25. Bonneterre J, Roche H, Kerbrat P etal. Epirubicin increases long-term survival in adjuvant chemotherapy of patients with poor-prognosis, node-positive, early breast cancer: 10-year follow-up results of the French Adjuvant Study Group 05 randomised trial. J Clin Oncol 2005; 23: 2686-2693.
26. Roser GL, Hargis JB, Hollis DR etal. Relationship between toxicity and obesity in women receiving adjuvant chemotherapy for breast cancer: results from cancer and leukemia group B study 8541. J Clin Oncol 1996; 14: 3000-3008.